David Coffey, MD
Internal Medicine · Hannibal, MONPI 1437474665
Payments from drug & device makers
Across 180 payments — averaging $16.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$751
- Amgen$304
- AstraZeneca$285
- GSK$268
- Novartis$261
- Novo Nordisk$175
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,053100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 60 | $751 |
| Amgen | 11 | $304 |
| AstraZeneca | 10 | $285 |
| GSK | 17 | $268 |
| Novartis | 18 | $261 |
| Novo Nordisk | 12 | $175 |
| Pfizer | 9 | $159 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $143 |
| Boehringer Ingelheim | 8 | $140 |
| Lilly USA, LLC | 5 | $80 |
| Astellas Pharma US Inc | 4 | $64 |
| Johnson & Johnson | 3 | $55 |
| Corcept Therapeutics | 2 | $53 |
| Lundbeck LLC | 3 | $49 |
| Otsuka America Pharmaceutical, Inc. | 3 | $46 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $33 |
| Sanofi-aventis U.S. LLC | 2 | $30 |
| Atricure, Inc. | 1 | $26 |
| Boston Scientific | 1 | $23 |
| Dexcom, Inc. | 1 | $17 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
| Viatris Specialty LLC | 1 | $16 |
| Bayer | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Sumitomo Pharma America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,053 in reported general payments places this provider in the 80th percentile of 2,097 internal medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 205 | $238,788 |
| TrulicityDulaglutide | 157 | $165,840 |
| EliquisApixaban | 120 | $132,505 |
| FarxigaDapagliflozin Propanediol | 159 | $118,227 |
| JardianceEmpagliflozin | 83 | $92,749 |
| MounjaroTirzepatide | 56 | $57,041 |
| VraylarCariprazine Hcl | 25 | $41,917 |
| MyrbetriqMirabegron | 54 | $38,948 |
| JanuviaSitagliptin Phosphate | 27 | $34,300 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 47 | $32,347 |
| Tresiba Flextouch U-200Insulin Degludec | 32 | $29,800 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 52 | $28,079 |
| XareltoRivaroxaban | 27 | $27,460 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $21,373 |
| GemtesaVibegron | 23 | $20,613 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $175 | $238,788205 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $80 | $222,881213 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $285 | $150,574206 claims |
| PfizerEliquis | $159 | $132,505120 claims |
| Boehringer IngelheimJardiance, Tradjenta | $140 | $101,46298 claims |
| AbbVieVraylar, Restasis, Linzess | $751 | $64,07061 claims |
| GSKBreo Ellipta, Anoro Ellipta, Trelegy Ellipta | $268 | $42,63068 claims |
| Astellas Pharma US IncMyrbetriq | $64 | $38,94854 claims |
| Johnson & JohnsonXarelto | $55 | $27,46027 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $13 | $20,61323 claims |
| NovartisEntresto | $261 | $14,90621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Hannibal
- Timothy SmithSaint Peters$21.4M
- Craig DietzKansas City$4M
- Michael ReschakSaint Louis$3.1M
- Dima DandachiColumbia$1.2M
- Santosh SharmaKansas City$782K
- Jianbo WangChesterfield$643K
- David PrelutskySaint Louis$575K
- Danish JabbarSaint Louis$510K
- Dubert GuerreroIndependence$369K
- Hany SalamaSaint Louis$279K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.